

Quality of care indicators in rectal cancer

P. Demetter¹, W. Ceelen², E. Danse³, K. Haustermans⁴, A. Jouret-Mourin⁵, A. Kartheuser⁶, S. Laurent⁷, G. Molle⁸, N. Nagy⁹, P. Scalliet¹⁰, E. Van Cutsem¹¹, M. Van Den Eynde¹², J. Van de Stadt¹³, E. Van Eycken¹⁴, J.-L. Van Laethem¹⁵, K. Vindevoghel¹⁶, F. Penninckx¹⁷

¹Pathology, Erasme University Hospital (ULB); ²Surgery, Ghent University Hospital (UG) ;
³Radiology, Cliniques Universitaires St.-Luc (UCL) ; ⁴Radiotherapy, Universitair Ziekenhuis Gasthuisberg (KUL) ; ⁵Pathology, Cliniques Universitaires St.-Luc (UCL) ; ⁶Surgery, Cliniques Universitaires St.-Luc (UCL); ⁷Gastroenterology, Ghent University Hospital (UG); ⁸Surgery, Hôpital de Jolimont; ⁹Pathology, CHU Charleroi; ¹⁰Radiotherapy, Cliniques Universitaires St.-Luc (UCL); ¹¹Gastroenterology, Universitair Ziekenhuis Gasthuisberg (KUL);
¹²Gastroenterology, Cliniques Universitaires St.-Luc (UCL); ¹³Surgery, Erasme University Hospital (ULB); ¹⁴Stichting Kankerregister, Brussels; ¹⁵Gastroenterology, Erasme University Hospital (ULB); ¹⁶Surgery, O.L.V. van Lourdes Ziekenhuis Waregem; ¹⁷Surgery, Universitair Ziekenhuis Gasthuisberg (KUL)

Corresponce: Pieter Demetter

Department of Pathology

Erasme University Hospital

Route de Lennik 808

B-1070 Bruxelles

Fax +32 (0)2 555 47 90

E-mail pieter.demetter@erasme.ulb.ac.be

ABSTRACT

Quality of health care is a hot topic, especially with regard to cancer. Although rectal cancer is, in many aspects, a model oncologic entity, there seem to be substantial differences in quality of care between countries, hospitals and physicians. PROCARE, a Belgian multidisciplinary national project to improve outcome in all patients with rectum cancer, identified a set of quality of care indicators covering all aspects of the management of rectal cancer. This set should permit national and international benchmarking, i.e. comparing results from individual hospitals or teams with national and international performances with feedback to participating teams. Such comparison could indicate whether further improvement is possible and/or warranted.

Quality of healthcare can be defined as “the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge”(1). This is a hot topic, especially for cancer care.

Rectal carcinoma is, in many aspects, a model oncologic entity. Major milestones in rectal cancer treatment during the past 25 years were the introduction of total mesorectal excision (TME) (2) and the development of a multimodal neo-adjuvant therapy concept (3). Nevertheless, there seem to be substantial differences in quality of care between countries, hospitals and physicians (4-6). To reduce hospital variation, most initiatives aim on selective referral, encouraging patients to seek care in high-volume hospitals, where cancer care is concentrated to site-specialist multidisciplinary teams (7). There is, however, a growing awareness that population-based audit of cancer services is essential to ensure high quality cancer care: as an alternative to volume-based referral, hospitals and surgeons can also improve their results by learning from their own outcome statistics and those from colleagues treating a similar patient group.

Although this is widely recognised, the vast majority of reports on the relation between quality and outcome of rectal cancer focuses on surgical outcomes mainly related to surgeon or hospital volume (8-10), level of surgical training (11), ethnicity or socio-economic status (12,13) of the patients. Those are in fact basically structural factors. The number of initiatives developing indicators to measure the quality of rectal cancer care taking into account the whole process from patient presentation to postoperative follow-up are scarce (14,15).

PROCARE (PROject on CANcer of the REctum), a Belgian multidisciplinary national project to improve outcome in all patients with rectum cancer (4,16,17), has been launched in 2006. Guidelines were made by a multidisciplinary group (18) and are also available on the web (19). Decentralised implementation of guidelines was organised by the scientific and professional organisations. Overall quality of care is assured by registration in a specific national database starting in 2006. Through feedback all centres are able to position themselves in comparison to national indicators. The quality of care indicators cover the following domains: diagnosis and staging, neoadjuvant treatment, surgery, adjuvant treatment, palliative treatment, follow-up and histopathologic examination. Some indicators cover most if not all of these items, and can be considered general quality indicators.

General quality indicators

In this group five indicators are considered: overall survival by stage, disease-specific survival by stage, disease-free survival, relative survival and proportion of patients with local recurrence.

Both survival and local recurrence rate are affected by most processes of rectal cancer care (18). Therefore, survival, disease-free survival and local recurrence are frequently used in clinical studies on rectal cancer (18,20-23).

Diagnosis and staging

With regard to these indicators, PROCARE considers proportion of patients (a) with a documented distance from the anal verge, (b) in whom a CT of the abdomen and X-ray or CT thorax was performed before any treatment, (c) in whom a CEA was performed before any treatment, (d) in whom complete large bowel-imaging was performed before undergoing elective surgery, (e) in whom a transrectal ultrasonography (TRUS) and pelvic CT and/or pelvic MRI were performed before any treatment and (f) with cStage II-III rectal cancer that have a reported cCRM (clinical circumferential resection margin). Other indicators taken into account are time between first histopathologic diagnosis and first treatment, accuracy of cM0 staging, accuracy of cT/cN staging in case of no or short radiotherapy, use of TRUS in cT1/cT2 stages, and use of MRI in cStage II or III.

The distance from the lower edge of the tumour to the anal verge is an important clinical parameter, since it co-determines the indication for neoadjuvant treatment, the type of surgery and the outcome (18,24,25). The aim of imaging techniques such as CT, MRI and PET is to detect hepatic and extrahepatic metastatic disease (18). A combined thorax and abdomen/pelvis spiral contrast-enhanced CT is recommended for routine use (14). Pre-treatment CEA levels have been related to cancer stage and survival independent of pTN stage in nonmetastatic colorectal cancer (18). Therefore, the serum CEA level should be determined in all patients before the start of any treatment (25). It is recommended that patients with rectal cancer undergo a total colonoscopy with resection of concomitant polyps if possible (18). However, if colonoscopy is judged to be too risky or if colonoscopy is refused, a high-quality double contrast barium enema or virtual colonoscopy should be performed (14,24-26). Patients with rectal cancer should have locoregional cTN staging. TRUS and high-resolution MRI (or CT) play an important role in the staging of rectal cancer (18). An important outcome of the preoperative staging is the CRM, which is a predictor of local and distant recurrence as well as survival (27-32). The CRM can be reliably predicted by preoperative high-resolution MRI (18). According to the guidelines of the Association of Coloproctology of Great Britain and Ireland (ACPGBI), the interval between making a diagnosis of cancer and the start of treatment should be less than 4 weeks (18,33).

Neoadjuvant treatment

In this category seven indicators are considered: proportion of cStage I patients that received neoadjuvant radio(chemo)therapy, proportion of cStage II-III patients (a) that received a neoadjuvant pelvic radiotherapy (RT), (b) treated with neoadjuvant 5-FU based chemoradiation that received a continuous infusion of 5-FU, (c) treated with a long course of

preoperative pelvic RT or chemoradiation that completed this neoadjuvant treatment within the planned timing and (d) treated with a long course of preoperative pelvic RT or chemoradiation that was operated 4 to 12 weeks after completion of the (chemo)radiation, the proportion of patients with cCRM \leq 2mm on MRI/CT that received long course neoadjuvant radio(chemo)therapy, and the rate of acute grade 4 radio(chemo)therapy-related complications.

Preoperative (chemo)radiation therapy has become a common practice for stage II and III rectal cancers (34). It has been well documented that neoadjuvant chemoradiation induces tumour regression and downstaging, and therefore increases tumour resectability and the rate of sphincter preservation (35-37). Furthermore, as shown by a large, prospective, randomised trial conducted by the German Rectal Cancer Study Group (3), this treatment modality results in a significantly reduced rate of local recurrence and treatment toxicity when compared with postoperative chemoradiation, while preoperative chemoradiation does not seem to offer survival advantage. Although many quality indicators on chemotherapy and radiotherapy are identified in the literature (24-26), none of these specifically address neoadjuvant treatment. Therefore, the PROCARE recommendations on neoadjuvant treatment were used as a basis to formulate additional indicators (18).

Surgery

The list of surgery-related quality of care indicators includes 10 items: (a) proportion of R0 resections, (b) (y)p distal margin involved (positive) after SSO or Hartmann's procedure for low rectal cancer (\leq 5cm), (c) mesorectal (y)pCRM positivity after radical surgical resection, (d) proportion of abdominoperineal anorectal excision (APR), Hartmann's procedure or proctocolectomy with definitive ileostomy, (e) proportion of patients with stoma 1 year after sphincter-sparing surgery, (f) major leakage after partial mesorectal excision (PME) + SSO + reconstruction, (g) major leakage after TME + SSO + reconstruction (global, i.e. with or without primary derivative stoma), (h) inpatient or 30-day mortality, (i) rate of intra-operative rectal perforation and (j) postoperative major surgical morbidity requiring reintervention under narcosis after radical surgical resection.

Curative resection rate is used very often as a quality indicator (14,25,26). Indeed, the main emphasis of surgery is to obtain clear surgical margins yielding a curative R0 resection (no residual tumour) (15). TME has been considered the optimal surgical modality for the treatment of rectal cancer since Heald *et al.* reported TME in 1982 (2); therefore, the proportion of APR and Hartmann's procedure is considered a very important quality indicator (being an outcome of importance to patients) (26). Surgeons should aim, wherever possible and desirable, to preserve the anal sphincter (18). A temporary defunctioning stoma should be considered each time the anastomosis is at risk for leakage after sphincter-sparing surgery (18). In general, a temporary stoma is closed within 1 year after surgery, i.e. after the end of adjuvant chemotherapy. Inpatient or 30-day mortality is an outcome that is affected

by many factors (14,18,26), such as stage, age, comorbidity, mode of surgery i.e. elective/scheduled vs. urgent/emergency. These factors need to be taken into account at risk-adjustment for appropriate interpretation of this indicator (26). Intra-operative perforation increases local recurrence and decreases survival; it occurs more frequently during APR as compared with anterior resection (18).

Adjuvant treatment

For this item the PROCARE Workgroup selected five quality indicators: (a) proportion of (y)pStage III patients with R0 resection that received adjuvant chemotherapy within 3 months after surgery, (b) proportion of pStage II-III patients with R0 resection that received adjuvant radiotherapy or chemoradiotherapy within 3 months after surgery, (c) proportion of (y)pStage II-III patients with R0 resection that started adjuvant chemotherapy within 12 weeks after surgical resection, (d) proportion of (y)pStage II-III patients with R0 resection treated with adjuvant chemo(radio)therapy, that received 5-FU based chemotherapy and (e) rate of acute grade 4 chemotherapy-related complications.

The rationale for early adjuvant therapy is that it is able to treat micrometastatic disease at a time when tumour burden is at a minimum. 5-FU given by intravenous injection for 5 days every 4 weeks for 6 cycles is the regimen for which the most evidence is available and that is clearly effective in prolonging survival in patients with stage III (18). Treatment with chemotherapy is associated with an acceptable complication rate. However, the occurrence of complication is dose-dependent and can be kept low artificially by lowering the dose.

Palliative treatment

The proportion of cStage IV patients receiving chemotherapy is the only quality indicator that was retained in this setting. The aim of palliative systemic therapy is to improve survival and quality of life in patients with metastatic disease (18).

Follow-up

In this domain, the rate of curatively treated patients that received a colonoscopy within 1 year after resection, and late grade 4 complications of radiotherapy or chemoradiation were selected.

For curatively treated patients it is recommended to perform a colonoscopy within 1 year after resection; the aim is to detect local recurrence at an early potentially (surgically) curable stage, and to detect new primary tumours (18,26).

Histopathologic examination

The list of quality indicators in the domain of histopathologic examination includes (a) the use of a specific pathology report sheet, (b) the quality of TME according to Quirke (38,39)

mentioned in the pathology report, (c) the distal tumour-free margin mentioned in the pathology report, (d) the number of lymph nodes examined, (e) the (y)pCRM mentioned in mm in the pathology report, and (f) the tumour regression grade (40) mentioned in the pathology report (after neoadjuvant treatment).

The quality of TME according to Quirke, the harvested lymph nodes and the status of the circumferential resection margin illustrate the quality of TME and affect the patient's oncological outcome (38,41-44). The pathologist should find as many lymph nodes as possible. The median number found is an indication of the quality of the pathological examination. According to the current TNM guidelines at least 12 lymph nodes need to be examined in rectal cancer specimens (45), but higher numbers are desirable and achievable in most cases, even after preoperative radiotherapy (46). Examining greater number of nodes increases the likelihood of proper staging (47). Yields will vary in relation to many factors; they can, however, be maximised through high-quality surgery and diligent pathological examination (48). Examination of 6 or fewer lymph nodes is related to poor prognosis (49). Best practice demands the reporting of CRM by radiologists and pathologists alike (28,29,38). Grading of tumour regression is important since outcome is better in case of complete regression than in case of residual microscopic disease which, in turn, is associated with better prognosis than cases without or with only minor regression (40,50-52).

CONCLUSIONS AND PROSPECTS

Patients deserve consistent standards regardless of where they live or are treated. The pursuit of excellence requires the definition of standards and the search is on to find what parameters best guarantee equal patient outcome and care.

Based on literature search and expert opinions, the PROCARE Workgroup has identified a set of quality of care indicators (summarised in the table) covering all aspects of the management of rectal cancer. Ideally population-based audit should be risk-adjusted; such approach requires intensive collaboration between clinicians and statisticians. In order to provide teams with simple, userfriendly but relevant feedback information, it might be useful to construct one quality index for the outcome (aggregating e.g. overall survival, proportion of R0 resections and postoperative major surgical morbidity with reintervention under narcosis after radical surgical resection) and one quality index for the process of treating rectal cancer (with e.g. time between first histopathological diagnosis and first treatment, proportion of APR and Hartmann's procedure or total excision of colon and rectum with definitive ileostomy, and number of lymph nodes examined).

In addition to national benchmarking, i.e. comparing results from individual hospitals or teams with national performances with feedback to participating teams, we should also aim for international benchmarking. This comparison could indicate whether further improvement is possible and/or warranted.

GENERAL QUALITY INDICATORS
Overall survival by stage
Disease-specific survival by stage
Disease-free survival
Relative survival
Proportion of patients with local recurrence
DIAGNOSIS AND STAGING
Proportion of patients with a documented distance from the anal verge
Proportion of patients with abdominal CT and thoracic X-ray or CT before any treatment
Proportion of patients in whom a CEA was performed before any treatment
Proportion of patients with complete large bowel-imaging before elective surgery
Proportion of patients with TRUS and pelvic CT and/or pelvic MRI before any treatment
Proportion of patients with cStage II-III rectal cancer that have a reported cCRM
Time between first histopathologic diagnosis and first treatment
Accuracy of cM0 staging
Accuracy of cT/cN staging in case of no or short radiotherapy
Use of TRUS in cT1/cT2 stages
Use of MRI in cStage II or III
NEOADJUVANT TREATMENT
Proportion of cStage I patients that received neoadjuvant radio(chemo)therapy
Proportion of cStage II-III patients that received a neoadjuvant pelvic radiotherapy
Proportion of cStage II-III patients with neoadjuvant chemoradiation that received a continuous 5-FU infusion
Proportion of patients completing long course neoadjuvant pelvic RT or chemoradiation within planned timing
Proportion of patients operated 4 to 12 weeks after completion of long course pelvic RT or chemoradiation
Proportion of patients with cCRM < or = 2mm that received long course neoadjuvant radio(chemo)therapy
Rate of acute grade 4 radio(chemo)therapy-related complications
SURGERY
Proportion of R0 resections
(y)p distal margin involved (positive) after SSO or Hartmann's procedure for low rectal cancer (< or = 5cm)
Mesorectal (y)pCRM positivity after radical surgical resection
Proportion of APR, Hartmann's procedure or proctocolectomy with definitive ileostomy
Proportion of patients with stoma 1 year after sphincter-sparing surgery
Major leakage after partial mesorectal excision + SSO + reconstruction
Major leakage after TME + SSO + reconstruction (global, i.e. with or without primary derivative stoma)
Inpatient or 30-day mortality
Rate of intra-operative rectal perforation
Postoperative major surgical morbidity requiring reintervention under narcosis after radical surgical resection
ADJUVANT TREATMENT
Proportion of (y)pStage III patients with R0 resection receiving adjuvant chemotherapy within 3 months
Proportion of pStage II-III patients with R0 resection receiving adjuvant (chemo)radiotherapy within 3 months
Proportion of (y)pStage II-III patients with R0 resection that started adjuvant chemotherapy within 12 weeks
Proportion of (y)pStage II-III patients with R0 resection treated with adjuvant chemotherapy receiving 5-FU
Rate of acute grade 4 chemotherapy-related complications
PALLIATIVE TREATMENT
Proportion of cStage IV patients receiving chemotherapy
FOLLOW-UP
Rate of curatively treated patients that received a colonoscopy within 1 year after resection
Late grade 4 complications of radiotherapy or chemoradiation
HISTOPATHOLOGIC EXAMINATION
Use of a specific pathology report sheet
Quality of TME according to Quirke mentioned in the pathology report
Distal tumour-free margin mentioned in the pathology report
Number of lymph nodes examined
(y)pCRM mentioned in mm in the pathology report
DEMENTER Expression grade mentioned in the pathology report

REFERENCES

1. Lohr KN, editor. Medicare: a strategy for quality assurance. Washington (DC): National Academy Press; 1990.
2. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery – clue to pelvic recurrence? *Br J Surg* 1982; 69: 613-616.
3. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, *et al.* Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004; 351: 1731-1740.
4. Penninckx F, Van Eycken L, Michiels G, Mertens R, Bertrand C, De Coninck D, *et al.* Survival of rectal cancer patients in Belgium 1997-98 and the potential benefit of a national project. *Acta Chir Belg* 2006; 106: 149-157.
5. van Gijn W, van de Velde CJ. Quality assurance through outcome registration in colorectal cancer: an ECCO initiative for Europe. *Acta Chir Jugosl* 2010; 57: 17-21.
6. Morris EJ, Sandin F, Lambert PC, Bray F, Klint A, Linklater K, *et al.* A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004. *Gut* 2011 Feb 8 [Epub ahead of print].
7. van Gijn W, van de Velde CJ; members of the EURECCA consortium. Improving quality of cancer care through surgical audit. *Eur J Surg Oncol* 2010; 36 Suppl 1: S23-S26.
8. Kressner M, Bohe M, Cedermark B, Dahlberg M, Damber L, Lindmark G, *et al.* The impact of hospital volume on surgical outcome in patients with rectal cancer. *Dis Colon Rectum* 2009; 52: 1542-1549.
9. Elferink MA, Krijnen P, Wouters MW, Lemmens VE, Jansen-Landheer ML, van de Velde CJ, *et al.* Variation in treatment and outcome of patients with rectal cancer by region, hospital type and volume in the Netherlands. *Eur J Surg Oncol* 2010; 36 Suppl 1: S74-S82.
10. Nugent E, Neary P. Rectal cancer surgery: volume-outcome analysis. *Int J Colorectal Dis* 2010; 25: 1389-1396.
11. Martling A, Holm T, Rutqvist LE, Johansson H, Moran BJ, Heald RJ, *et al.* Impact of a surgical training programme on rectal cancer outcomes in Stockholm. *Br J Surg* 2005; 92: 225-229.

12. Shaw C, Blakely T, Sarfati D, Fawcett J, Peace J. Trends in colorectal cancer mortality by ethnicity and socio-economic position in New Zealand, 1981-99: one country, many stories. *Aust N Z J Public Health* 2006; 30: 64-70.
13. Cavalli-Björkman N, Lambe M, Eaker S, Sandin F, Glimelius B. Differences according to educational level in the management and survival of colorectal cancer in Sweden. *Eur J Cancer* 2011 Jan 13 [Epub ahead of print].
14. Gagliardi AR, Simunovic M, Langer B, Stern H, Brown AD. Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach. *Can J Surg* 2005; 48: 441-452.
15. Vergara-Fernandez O, Swallow CJ, Victor JC, O'Connor BI, Gryphe R, MacRae HM, *et al.* Assessing outcomes following surgery for colorectal cancer using quality of care indicators. *J Can Chir* 2010, 53: 232-240.
16. Penninckx F, Danse E; PROCARE Workgroup. On the role of radiologists in the Belgian PROject on CANcer of the REctum, PROCARE. *JBR-BTR* 2006; 89: 19-22.
17. Leonard D, Penninckx F, Fieuws S, Jouret-Mourin A, Sempoux C, Jehaes E, *et al.* Factors predicting the quality of total mesorectal excision for rectal cancer. *Ann Surg* 2010; 252: 982-988.
18. Penninckx F, Roels S, Leonard D, Laurent S, Decaestecker J, De Vleeschouwer C, *et al.* Kwaliteit van rectale kankerzorg, fase 1: Een praktijkrichtlijn voor rectale kanker. Good Clinical Practice (GCP). Brussel: Federaal Keniscentrum voor de Gezondheidszorg (KCE); KCE reports 69A, 2007.
19. Belgian Cancer Registry. Multidisciplinary Belgian Project on Cancer of the Rectum (PROCARE). Multidisciplinary guidelines for the treatment of rectal cancer, available at: www.kankerregister.be.
20. den Dulk M, van de Velde CJ. Quality assurance in surgical oncology: the tale of the Dutch rectal cancer TME trial. *J Surg Oncol* 2008; 97: 5-7.
21. Katoh H, Yamashita K, Wang G, Sato T, Nakamura T, Watanabe M. Prognostic significance of preoperative bowel obstruction in stage III colorectal cancer. *Ann Surg Oncol* 2011 Mar 3 [Epub ahead of print].
22. Yasuda K, Sunami E, Kawai K, Nagawa H, Kitayama J. Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer. *J Gastrointest Cancer* 2011 Mar 3 [Epub ahead of print].

23. Yoon WS, Park W, Choi DH, Ahn YC, Chun HK, Lee WY, *et al.* Which patients benefit from preoperative chemoradiotherapy for intermediate staged rectal cancer? *Onkologie* 2011; 34: 36-41.
24. Malin JL, Schneider EC, Epstein AM, Adams J, Emanuel EJ, Kahn KL. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? *J Clin Oncol* 2006; 24: 626-634.
25. McGory ML, Shekelle PG, Ko CY. Development of quality indicators for patients undergoing colorectal cancer surgery. *J Natl Cancer Inst* 2006; 98: 1623-1633.
26. Patwardhan MB, Samsa GP, McCrory DC, Fisher DA, Mantyh CR, Morse MA, *et al.* Cancer care quality measures: diagnosis and treatment of colorectal cancer. *Evid Rep Technol Assess (Full Rep)* 2006; 138: 1-116.
27. Bernstein TE, Endreseth BH, Romundstad P, Wibe A; Norwegian Colorectal Cancer Group. Circumferential resection margin as a prognostic factor in rectal cancer. *Br J Surg* 2009; 96: 1348-1357.
28. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? *J Clin Oncol* 2008; 26: 303-312.
29. Maugham NJ, Quirke P. Modern management of colorectal cancer – a pathologists’s view. *Scand J Surg* 2003; 92: 11-19.
30. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumor spread and surgical excision. *Lancet* 1986; 2: 996-999.
31. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, *et al.* Role of circumferential margin involvement in the local recurrence of rectal cancer. *Lancet* 1994; 344:707-11.
32. Wibe A, Rendedal PR, Svensson E, Norstein J, Eide TJ, Myrvold HE, *et al.* Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. *Br J Surg* 2002; 89: 327-334.
33. ACPGI. Guidelines for the management of colorectal cancer. The Association of Coloproctology of Great Britain and Ireland, 2007.
34. Balch GC, De Meo A, Guillem JG. Modern management of rectal cancer : a 2006 update. *World J Gastroenterol* 2006; 12: 3186-3195.

35. Chen ET, Mohiuddin M, Brodovsky H, Fishbein G, Marks G. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. *Int J Radiat Oncol Biol Phys* 1994; 30: 169-175.
36. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, *et al.* Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M.D. Anderson Cancer Center experience. *Int J Radiat Oncol Biol Phys* 1999; 44: 1027-1038.
37. Minsky BD, Cohen AM, Enker WE, Paty P. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. *Int J Radiat Oncol Biol Phys* 1995; 31: 553-559.
38. Nagtegaal ID, van de Velde CJ, van der Worp E, Kapitein E, Quirke P, van Krieken JHJM, *et al.* Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. *J Clin Oncol* 2002; 20: 1729-1734.
39. Sebag-Montefiore D, Quirke P, Steele RJ. CR07: Pre-operative radiotherapy and selective post-operative chemotherapy in rectal cancer. Available at: www.ctu.mrc.ac.uk/studies/cr07.asp.
40. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. *Int J Colorect Dis* 1997; 12: 19-23.
41. Maslekar S, Sharma A, MacDonald A, Gunn J, Monson JRT, Hartley JE. Mesorectal grades predicts recurrences after curative resection for rectal cancer.
42. Lee HY, Choi HJ, Park KJ, Shin JS, Kwon HC, Roh MS, *et al.* Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. *Ann Surg Oncol* 2007; 14: 1712-1717.
43. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, *et al.* Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. *J Clin Oncol* 2003; 21: 2912-2919.
44. Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. *Ann Surg Oncol* 2003; 10: 65-71.
45. TNM classification of malignant tumours. 7th edn. New York: Wiley; 2010.
46. Mekenkamp LJM, van Krieken JHJM, Marijnen CAM, van de Velde CJH, Nagtegaal ID, for the Pathology Review Committee and the Co-operative Clinical Investigators. Lymph node retrieval in rectal cancer is dependent on many factors – the role of the

tumor, the patient, the surgeon, the radiotherapist, and the pathologist. *Am J Surg Pathol* 2009; 33: 1547-1553.

47. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB 3rd, *et al.* Impact of number of nodes retrieved on outcome in patients with rectal cancer. *J Clin Oncol* 2001; 19: 157-163.
48. Morris EJA, Maughan NJ, Forman D, Quirke P. Identifying stage III colorectal cancer patients: the influence of the patient, surgeon, and pathologist. *J Clin Oncol* 2007; 25: 2573-2579.
49. Caplin S, Cerottini J-P, Bosman FT, Constanda MT, Givel J-C. For patients with Dukes' B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. *Cancer* 1998; 83: 666-672.
50. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. *Cancer* 2002; 94: 1121-1130.
51. Rödel C, Martus P, Papadopoulos T, Füzesi L, Klimpfinger M, Fietkau R, *et al.* Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. *J Clin Oncol* 2005; 23: 8688-8696.
52. Quirke P. Pathology for the radiologist. Pathological insights into colorectal cancer. In: Brown G, editor. *Contemporary issues in cancer imaging. Colorectal cancer.* Cambridge: University Press; 2007.